A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.

CONCLUSIONS: Pegylated liposomal doxorubicin in combination with bevacizumab has activity in advanced KS, but it is unclear if the combination yields better outcomes than liposomal doxorubicin used alone.
PMID: 30979736 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 11, 2019 Category: Cancer & Oncology Authors: Ramaswami R, Uldrick TS, Polizzotto MN, Wyvill KM, Goncalves P, Widell A, Lurain K, Steinberg SM, Figg WD, Tosato G, Whitby D, Yarchoan R Tags: Clin Cancer Res Source Type: research